Hanyu Pharmaceutical announced that Pingshan Branch underwent routine supervision and inspection by the US FDA from June 18 to 26, 2026, and recently received an EIR report issued by the FDA. The inspection findings were VAI, and the quality management system complies with the US FDA cGMP requirements. This is the second time since the Pingshan branch first passed the FDA pre-approval inspection in July-August 2023, and successfully passed the FDA inspection.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.